No current GLP-1 label lists Alzheimer's and dementia as an approved use, so prescribing one for it would be off-label. evoke and evoke+ (Semaglutide tablets): Over 104 weeks, decline on the CDR-SB scale was 2.3 and 2.2 points on semaglutide against 2.3 and 2.1 on placebo. The authors conclude it was not efficacious in slowing early Alzheimer's disease. ClinicalTrials.gov lists 15 trials of these medicines on it: 3 with posted results and 3 recruiting now.
Read from the registry and PubMed every day. The newest update here is Oct 16, 2026.
Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.
Semaglutide tablets · 3,808 people · No clear benefit · Placebo-controlled randomized trial
Over 104 weeks, decline on the CDR-SB scale was 2.3 and 2.2 points on semaglutide against 2.3 and 2.1 on placebo. The authors conclude it was not efficacious in slowing early Alzheimer's disease.
A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.
| Medicine | Trials | Posted results | Recruiting |
|---|---|---|---|
| Semaglutide | 9 | 2 | 2 |
| Liraglutide | 4 | 0 | 0 |
| Exenatide | 1 | 1 | 0 |
| Mazdutide | 1 | 0 | 1 |
Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.
| Trial | Medicine | Phase | People | Result |
|---|---|---|---|---|
| NCT05891496A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease | Semaglutide | Phase 3 | 23 | Change in Gene Expression Assessed by Single-cell Ribonucleic Acid Sequencing (scRNAseq) (Cells in Cerebrospinal Fluid [CSF]) (Differentially expressed genes), Baseline (week 0), week 12. Semaglutide: 41.25; Placebo: 21.00. |
| NCT01255163A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease | Exenatide | Phase 2 | 57 | Number of Participants With Incidence of Nausea (Participants), 18 months. Exendin-4: 5; Placebo: 0. |
| NCT05768945Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors | Semaglutide | Not phased | 742,670 | Time to Dementia Onset (Incidence rate per 1000 person year), Median follow up times: 1) 98 days (exp), 134 days (ref) 2) 118 days (exp), 132 days (ref) 3) 90 days (exp), 308 days (ref) 4) 99 days (exp), 135 days (ref), Analysis 1. Semaglutide: 4.40; DPP4 Inhibitors: 6.06. |
The registry page names each site and who can enroll. Ask your clinician before joining one.
| Trial | Medicine | Phase | Expected to finish |
|---|---|---|---|
| Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study) | Mazdutide | Phase 3 | Aug 1, 2029 |
| COMMETS- Combination MCI Metabolic Syndrome | Semaglutide | Phase 2 | Dec 1, 2028 |
| Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease | Semaglutide | Phase 1/2 | Dec 2029 |
Meta-analysis · Nutrients · Oct 9, 2026 · Abbatecola AM et al.
Meta-analysis · Curr Neuropharmacol · May 15, 2026 · Xu H et al.
Randomized trial · Clin Infect Dis · May 1, 2026 · Atieh O et al. · cited by 6
Systematic review · Int J Mol Sci · Apr 29, 2026 · Mahoon DA et al.
Meta-analysis · Diabetes Obes Metab · Feb 10, 2026
Meta-analysis · J Diabetes Complications · Jan 26, 2026 · Stefanou MI et al. · cited by 4
Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.
evoke and evoke+ (Semaglutide tablets, 3,808 people): Over 104 weeks, decline on the CDR-SB scale was 2.3 and 2.2 points on semaglutide against 2.3 and 2.1 on placebo. The authors conclude it was not efficacious in slowing early Alzheimer's disease.
Not in any current label we read. A prescriber can still use a medicine off-label, but insurance often limits coverage to approved uses, so ask your plan.
Semaglutide, with 9 registered trials on it, then Liraglutide with 4. More trials do not mean better results: read what each posted.
3 trials are recruiting on ClinicalTrials.gov now, listed below with their registry pages, which name each site and who can enroll.